1 patent currently held
55 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2043. from the record
Of the 55 now held by other companies, 29 were conveyed to Merck Sharp and Dohme LLC in the filing they arrived in, and 26 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2043
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Mar 2033 · High confidence
The most cited patent in this portfolio, cited by 47 later US patents, top 10% of utility patents granted in 2017 in our data. Protection runs to 2033.
conveyed to Pharmaron Inc. - now held by Valo Health, Inc.
Also notable
Ends Mar 2037 · High confidence
Cited by 24 later US patents, top 10% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2037.
conveyed to Pharmaron Inc. - now held by Gilead Apollo, LLC
Also notable
Ends Sep 2031 · High confidence
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2031.
conveyed to Pharmaron Inc. - now held by Valo Health, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Gabaa Positive Allosteric Modulator Compounds, Methods of Making, and Uses Thereof | 1 in force | to Jun 2043 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,617,794 | Gabaa Positive Allosteric Modulator Compounds, Methods of Making, and Uses Thereof held by Pharmaron Beijing Co. Ltd. (China) In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 55 patents in force now held by others · 7 patents ended · 6 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
2 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.